Abstract library

20 results for "Ficial".
#769 Surgicial Management of Gastroenteropancreatic Neuroendocrine Tumors: Early and Long-Term Results
Introduction: Surgery could improve survival of gastroenteropancreatic neuroendocrine tumors (GEP NET). Nevertheless, data on survival prognostic factors come from studies focusing on heterogeneous population including both resected and non-resected patients.
Conference: 10th Annual ENETS Conference (2013)
Category: Surgical treatment
Presenting Author: Nadia Russolillo
Keywords: GEP-NET, surgery
#1174 Long-Term Follow-Up of Resected Small (< 2 Cm) Asymptomatic Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors: Correlation Between Type of Resection, Histopathologic Features, and Outcome
Introduction: The surgical management of small, incidentally found sporadic non-functioning pancreatic neuroendocrine tumors (NF-PNET) is controversial
Conference: 12th Annual ENETS Conference (2015)
Category: Surgical treatment
Presenting Author: MD Anna Malpaga
Keywords: small
#1834 Sporadic Panglandular Non-Functioning pNET: New Entities? A Case Series
Introduction: Sporadic panglandular pancreatic neuroendocrine tumors (PanNETs) have never been described yet.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Caterina Costanza Zingaretti
#402 Single-Center Treatment Outcomes in Patients (pts) with High Grade Neuroendocrine Carcinoma of the Uterine Cervix (cNEC)
Introduction: cNEC is a rare and aggressive cancer; the best treatment is unknown.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Boris Naraev
#409 Activation of cdk4/Cyclind D1 and the Associated Attenuation of Rb Function in Pancreatic Neuroendocrine Tumors (Pan-NETs)
Introduction: Pan-NET poses challenges in clinical management due to the lack of identifications of key oncogenic pathways in this neoplasm. There are no reliable biomarkers to predict the recurrence and progression and treatment option is limited. Genetic changes in Rb pathway can lead to Pan-NET formation in mice. Genomic investigations in humans have not revealed Rb pathway mutation.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Laura Tang
Authors: Tang L, ...
#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center
Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Richard P Baum
Keywords: PRRT
#1079 CT Imaging Findings of Gastric Neuroendocrine Neoplasm According to 2010 WHO Classification
Introduction: Gastric neuroendocrine neoplasm(G-NEN) is rarely detected at an early stage. Its prognosis varies based on grade and stage.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: ZH W Liang
Authors: Jiang L M, Liang Z W, Li Y, Geng C Y, ...
#1084 Pancreatic Neuroendocrine Tumors in Denmark and Introduction of Cancer Package Pathways
Introduction: New referral procedures were introduced into the Danish healthcare system on Jan 1, 2009 in malignant diseases. Cancer-package pathways purposed to streamline diagnostics and treatment specifically to reduce the waiting time from diagnosis to initiation of specialized treatment.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: BA Claus Uhrenholt Christensen
Authors: Christensen C U, Grønbæk H, ...
#1293 The Role of Hepatic Intra-arterial Therapies in Metastatic Neuroendocrine Tumours (NETs): A Specialist Center Experience.
Introduction: Liver metastases are relatively common in patients with NETs, having a negative impact on prognosis. The options for selective liver metastases therapy are limited to catheter guided procedures: TACE, TAE or SIRT. Data regarding the effectiveness & safety of these procedures in different types of NETs is limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MD Simona Glasberg
#1363 Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.